-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Nuocheng Jianhua announced today that the company's new multi-target receptor tyrosine kinase (RTK) inhibitor ICP-033 New Drug Research (IND) application has been accepted by the National Medical Products Administration (NMPA).
By acting on receptors such as discoid domain receptor 1/2 (DDR1/2), vascular endothelial growth factor receptor 2/3 (VEGFR 2/3), and platelet-derived growth factor receptor (PDGFR α/β) The amino acid kinase, ICP-033 can inhibit tumor angiogenesis, improve the tumor microenvironment, inhibit tumor growth, invasion and metastasis, thereby exerting target-specific anti-tumor effects.
ICP-033 is a class 1 innovative drug of Nuocheng Jianhua with global independent intellectual property rights.